<p>法國巴黎銀行金融市場在最近向證券交易委員會（SEC）提交的 13F 文件中表示，在第四季度將其在西氏醫藥服務公司（NYSE:WST - 免費報告）的持股增加了 30.8%。該基金在季度內額外購買了 41,416 股後，持有 175,899 股該醫療器械供應商的股票。截至其最近向證券交易委員會（SEC）提交的文件，法國巴黎銀行金融市場持有西氏醫藥服務公司 0.24% 的股份，價值 57,617,000 美元。</p>
<ul>
<li>3 只有潛力增加股息的股息冠軍</li>
</ul>
<p>其他對沖基金最近也增加或減少了在該公司的持股。Whipplewood Advisors LLC 在第四季度以約 25,000 美元的估值新建了西氏醫藥服務公司的股份。Retirement Wealth Solutions LLC 在第四季度以約 34,000 美元的估值新建了西氏醫藥服務公司的股份。Centricity Wealth Management LLC 在第四季度以 35,000 美元的估值購買了西氏醫藥服務公司的股份。Cornerstone Planning Group LLC 在第四季度將其在西氏醫藥服務公司的股份增加了 57.1%。Cornerstone Planning Group LLC 現在擁有 110 股該醫療器械供應商的股票，價值 38,000 美元，此前在該期間內又購買了 40 股。最後，Private Trust Co. NA 在第四季度將其在西氏醫藥服務公司的股份增加了 138.6%。Private Trust Co. NA 現在擁有 136 股該醫療器械供應商的股票，價值 45,000 美元，此前在上個季度又購買了 79 股。93.90% 的股票由機構投資者和對沖基金持有。</p>
<h2>華爾街分析師預測增長</h2>
<p>多位分析師對 WST 股票發表了評論。德意志銀行將西氏醫藥服務公司的評級從 “持有” 上調至 “買入”，並在 2 月 14 日的研究報告中設定了 250.00 美元的目標價。KeyCorp 將西氏醫藥服務公司的目標價從 470.00 美元下調至 325.00 美元，並在 2 月 14 日的研究報告中對該股票給予 “增持” 評級。Evercore ISI 在 3 月 18 日的研究報告中開始覆蓋西氏醫藥服務公司的股票，給予 “跑贏大盤” 評級，並設定 275.00 美元的目標價。花旗集團在 1 月 8 日的報告中開始覆蓋西氏醫藥服務公司的股票，給予 “買入” 評級，並設定 400.00 美元的目標價。最後，StockNews.com 在 2 月 27 日的報告中將西氏醫藥服務公司的股票評級從 “買入” 下調至 “持有”。兩位分析師對該股票給予持有評級，六位給予買入評級，一位給予強烈買入評級。根據 MarketBeat 的數據，西氏醫藥服務公司的平均評級為 “適度買入”，平均目標價為 332.50 美元。</p>
<ul>
<li>今年將推動標準普爾 500 表現的因素是什麼？</li>
</ul>
<p><strong>查看我們最新的 WST 股票報告</strong></p>
<h2>西氏醫藥服務公司的價格表現</h2>
<p>NYSE:WST 週三開盤價為 205.45 美元。該公司的 50 日移動平均價格為 217.46 美元，200 日移動平均價格為 279.88 美元。西氏醫藥服務公司在過去一年中的最低價為 187.43 美元，最高價為 372.52 美元。該公司的市值為 147.6 億美元，市盈率為 30.71，市盈增長比率為 6.74，貝塔係數為 1.14。該公司的債務與股本比率為 0.08，流動比率為 2.79，速動比率為 2.23。</p>
<ul>
<li>至少有 30 年股息增長的醫療保健股票</li>
</ul>
<p>西氏醫藥服務公司（NYSE:WST - 獲取免費報告）最近在 4 月 24 日發佈了季度收益數據。該醫療器械供應商報告季度每股收益為 1.45 美元，超出分析師一致預期的 1.22 美元，超出幅度為 0.23 美元。西氏醫藥服務公司的淨利潤率為 17.03%，股本回報率為 18.60%。該公司在本季度的收入為 6.98 億美元，而一致預期為 6.8524 億美元。在去年同期，該公司每股收益為 1.56 美元。與去年同期相比，該公司的收入增長了 0.4%。股票研究分析師預測西氏醫藥服務公司將在當前年度發佈 6.62 美元的每股收益。</p>
<h2>西氏醫藥服務公司宣佈分紅</h2>
<p>該公司最近還披露了一項季度分紅，將於 8 月 6 日（星期三）支付。7 月 30 日（星期三）的股東將獲得 0.21 美元的分紅。這相當於年化分紅為 0.84 美元，分紅收益率為 0.41%。除息日為 7 月 30 日（星期三）。西氏醫藥服務公司的分紅支付比率（DPR）目前為 13.19%。</p>
<h2>關於西氏醫藥服務公司</h2>
<p>（免費報告）</p>
<p>西氏醫藥服務公司設計、製造和銷售用於注射藥物和醫療保健產品的封閉和輸送系統，業務遍及美洲、歐洲、中東、非洲和亞太地區。該公司分為兩個部門，專有產品和合同製造產品。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票超過西氏醫藥服務公司</li>
<li>哪些華爾街分析師最準確？</li>
<li>3 只中型醫療股票表現優於市場</li>
<li>如何開始投資房地產</li>
<li>按市值排名的四月頂級內部購買</li>
<li>什麼是國債？</li>
<li>在弱勢收益和 CVS-Novo 合作後，禮來公司是否值得買入？</li>
</ul>
<p><strong>想看看其他對沖基金持有的 WST 嗎？</strong> 訪問 HoldingsChannel.com 獲取西氏醫藥服務公司（NYSE:WST - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在西氏醫藥服務嗎？</h2>
<p>在考慮西氏醫藥服務之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而西氏醫藥服務並不在名單上。</p>
<p>雖然西氏醫藥服務目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

西氏醫藥服務

<p>BNP Paribas 金融市場在第四季度將其在西氏醫藥服務公司（NYSE:WST）的持股比例增加了 30.8%，目前持有 175,899 股，價值 5760 萬美元。其他對沖基金也調整了他們的持倉。分析師對 WST 的評級不一，目標價格範圍在 250 美元到 400 美元之間。該股票開盤價為 205.45 美元，市值為 147.6 億美元，市盈率為 30.71。公司報告每股收益為 1.45 美元，超出預期，並宣佈季度股息為 0.21 美元</p>

<p>BNP Paribas Financial Markets increased its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 30.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 175,899 shares of the medical instruments supplier's stock after buying an additional 41,416 shares during the quarter. BNP Paribas Financial Markets owned 0.24% of West Pharmaceutical Services worth $57,617,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>法國巴黎銀行金融市場在最近向證券交易委員會（SEC）提交的 13F 文件中表示，在第四季度將其在西氏醫藥服務公司（NYSE:WST - 免費報告）的持股增加了 30.8%。該基金在季度內額外購買了 41,416 股後，持有 175,899 股該醫療器械供應商的股票。截至其最近向證券交易委員會（SEC）提交的文件，法國巴黎銀行金融市場持有西氏醫藥服務公司 0.24% 的股份，價值 57,617,000 美元。</p>
</div><ul>
<li>3 Dividend Champions with room for dividend growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只有潛力增加股息的股息冠軍</li>
</ul>
</div><p>Other hedge funds also recently added to or reduced their stakes in the company. Whipplewood Advisors LLC acquired a new position in shares of West Pharmaceutical Services during the fourth quarter valued at about $25,000. Retirement Wealth Solutions LLC acquired a new position in West Pharmaceutical Services during the 4th quarter valued at approximately $34,000. Centricity Wealth Management LLC purchased a new position in shares of West Pharmaceutical Services in the fourth quarter worth $35,000. Cornerstone Planning Group LLC lifted its stake in shares of West Pharmaceutical Services by 57.1% during the fourth quarter. Cornerstone Planning Group LLC now owns 110 shares of the medical instruments supplier's stock worth $38,000 after buying an additional 40 shares during the period. Finally, Private Trust Co. NA grew its holdings in shares of West Pharmaceutical Services by 138.6% during the fourth quarter. Private Trust Co. NA now owns 136 shares of the medical instruments supplier's stock valued at $45,000 after buying an additional 79 shares during the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他對沖基金最近也增加或減少了在該公司的持股。Whipplewood Advisors LLC 在第四季度以約 25,000 美元的估值新建了西氏醫藥服務公司的股份。Retirement Wealth Solutions LLC 在第四季度以約 34,000 美元的估值新建了西氏醫藥服務公司的股份。Centricity Wealth Management LLC 在第四季度以 35,000 美元的估值購買了西氏醫藥服務公司的股份。Cornerstone Planning Group LLC 在第四季度將其在西氏醫藥服務公司的股份增加了 57.1%。Cornerstone Planning Group LLC 現在擁有 110 股該醫療器械供應商的股票，價值 38,000 美元，此前在該期間內又購買了 40 股。最後，Private Trust Co. NA 在第四季度將其在西氏醫藥服務公司的股份增加了 138.6%。Private Trust Co. NA 現在擁有 136 股該醫療器械供應商的股票，價值 45,000 美元，此前在上個季度又購買了 79 股。93.90% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of analysts have commented on WST shares. Deutsche Bank Aktiengesellschaft raised West Pharmaceutical Services from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $250.00 price target for the company in a research report on Friday, February 14th. KeyCorp dropped their target price on West Pharmaceutical Services from $470.00 to $325.00 and set an &#34;overweight&#34; rating on the stock in a research report on Friday, February 14th. Evercore ISI initiated coverage on shares of West Pharmaceutical Services in a research report on Tuesday, March 18th. They set an &#34;outperform&#34; rating and a $275.00 price target for the company. Citigroup started coverage on shares of West Pharmaceutical Services in a report on Wednesday, January 8th. They issued a &#34;buy&#34; rating and a $400.00 price objective on the stock. Finally, StockNews.com cut shares of West Pharmaceutical Services from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday, February 27th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, West Pharmaceutical Services has an average rating of &#34;Moderate Buy&#34; and an average target price of $332.50.</p>
<div class="lb-trans"><p>多位分析師對 WST 股票發表了評論。德意志銀行將西氏醫藥服務公司的評級從 “持有” 上調至 “買入”，並在 2 月 14 日的研究報告中設定了 250.00 美元的目標價。KeyCorp 將西氏醫藥服務公司的目標價從 470.00 美元下調至 325.00 美元，並在 2 月 14 日的研究報告中對該股票給予 “增持” 評級。Evercore ISI 在 3 月 18 日的研究報告中開始覆蓋西氏醫藥服務公司的股票，給予 “跑贏大盤” 評級，並設定 275.00 美元的目標價。花旗集團在 1 月 8 日的報告中開始覆蓋西氏醫藥服務公司的股票，給予 “買入” 評級，並設定 400.00 美元的目標價。最後，StockNews.com 在 2 月 27 日的報告中將西氏醫藥服務公司的股票評級從 “買入” 下調至 “持有”。兩位分析師對該股票給予持有評級，六位給予買入評級，一位給予強烈買入評級。根據 MarketBeat 的數據，西氏醫藥服務公司的平均評級為 “適度買入”，平均目標價為 332.50 美元。</p>
</div><ul>
<li>What Factors Will Drive S&amp;P 500 Performance This Year?</li>
</ul>
<div class="lb-trans"><ul>
<li>今年將推動標準普爾 500 表現的因素是什麼？</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Report on WST</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 WST 股票報告</strong></p>
</div><h2>West Pharmaceutical Services Price Performance</h2>
<div class="lb-trans"><h2>西氏醫藥服務公司的價格表現</h2>
</div><p>NYSE:WST opened at $205.45 on Wednesday. The company has a 50 day moving average price of $217.46 and a 200-day moving average price of $279.88. West Pharmaceutical Services, Inc. has a 1-year low of $187.43 and a 1-year high of $372.52. The firm has a market cap of $14.76 billion, a price-to-earnings ratio of 30.71, a price-to-earnings-growth ratio of 6.74 and a beta of 1.14. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.79 and a quick ratio of 2.23.</p>
<div class="lb-trans"><p>NYSE:WST 週三開盤價為 205.45 美元。該公司的 50 日移動平均價格為 217.46 美元，200 日移動平均價格為 279.88 美元。西氏醫藥服務公司在過去一年中的最低價為 187.43 美元，最高價為 372.52 美元。該公司的市值為 147.6 億美元，市盈率為 30.71，市盈增長比率為 6.74，貝塔係數為 1.14。該公司的債務與股本比率為 0.08，流動比率為 2.79，速動比率為 2.23。</p>
</div><ul>
<li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li>
</ul>
<div class="lb-trans"><ul>
<li>至少有 30 年股息增長的醫療保健股票</li>
</ul>
</div><p>West Pharmaceutical Services (NYSE:WST - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The medical instruments supplier reported $1.45 earnings per share for the quarter, topping analysts' consensus estimates of $1.22 by $0.23. West Pharmaceutical Services had a net margin of 17.03% and a return on equity of 18.60%. The business had revenue of $698.00 million during the quarter, compared to the consensus estimate of $685.24 million. During the same quarter in the prior year, the firm posted $1.56 earnings per share. The company's revenue was up .4% compared to the same quarter last year. Equities research analysts forecast that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.</p>
<div class="lb-trans"><p>西氏醫藥服務公司（NYSE:WST - 獲取免費報告）最近在 4 月 24 日發佈了季度收益數據。該醫療器械供應商報告季度每股收益為 1.45 美元，超出分析師一致預期的 1.22 美元，超出幅度為 0.23 美元。西氏醫藥服務公司的淨利潤率為 17.03%，股本回報率為 18.60%。該公司在本季度的收入為 6.98 億美元，而一致預期為 6.8524 億美元。在去年同期，該公司每股收益為 1.56 美元。與去年同期相比，該公司的收入增長了 0.4%。股票研究分析師預測西氏醫藥服務公司將在當前年度發佈 6.62 美元的每股收益。</p>
</div><h2>West Pharmaceutical Services Announces Dividend</h2>
<div class="lb-trans"><h2>西氏醫藥服務公司宣佈分紅</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 6th. Stockholders of record on Wednesday, July 30th will be given a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date is Wednesday, July 30th. West Pharmaceutical Services's dividend payout ratio (DPR) is presently 13.19%.</p>
<div class="lb-trans"><p>該公司最近還披露了一項季度分紅，將於 8 月 6 日（星期三）支付。7 月 30 日（星期三）的股東將獲得 0.21 美元的分紅。這相當於年化分紅為 0.84 美元，分紅收益率為 0.41%。除息日為 7 月 30 日（星期三）。西氏醫藥服務公司的分紅支付比率（DPR）目前為 13.19%。</p>
</div><h2>About West Pharmaceutical Services</h2>
<div class="lb-trans"><h2>關於西氏醫藥服務公司</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.</p>
<div class="lb-trans"><p>西氏醫藥服務公司設計、製造和銷售用於注射藥物和醫療保健產品的封閉和輸送系統，業務遍及美洲、歐洲、中東、非洲和亞太地區。該公司分為兩個部門，專有產品和合同製造產品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than West Pharmaceutical Services</li>
<li>Which Wall Street Analysts are the Most Accurate?</li>
<li>3 Mid-Cap Medical Stocks Outperforming the Market</li>
<li>How to Start Investing in Real Estate</li>
<li>The Top-Ranked Insider Buys From April by Market Cap</li>
<li>What Are Treasury Bonds?</li>
<li>Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過西氏醫藥服務公司</li>
<li>哪些華爾街分析師最準確？</li>
<li>3 只中型醫療股票表現優於市場</li>
<li>如何開始投資房地產</li>
<li>按市值排名的四月頂級內部購買</li>
<li>什麼是國債？</li>
<li>在弱勢收益和 CVS-Novo 合作後，禮來公司是否值得買入？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding WST?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 WST 嗎？</strong> 訪問 HoldingsChannel.com 獲取西氏醫藥服務公司（NYSE:WST - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=WST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in West Pharmaceutical Services Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在西氏醫藥服務嗎？</h2>
</div><p>Before you consider West Pharmaceutical Services, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮西氏醫藥服務之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而西氏醫藥服務並不在名單上。</p>
</div><p>While West Pharmaceutical Services currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然西氏醫藥服務目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

法國巴黎銀行金融市場增持了西氏醫藥服務公司（NYSE:WST）的股份